BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
| Author | Chemaitelly, Hiam |
| Author | Ayoub, Houssein H. |
| Author | Coyle, Peter |
| Author | Tang, Patrick |
| Author | Yassine, Hadi M. |
| Author | Al Thani, Asmaa A. |
| Author | Al-Khatib, Hebah A. |
| Author | Hasan, Mohammad R. |
| Author | Al-Kanaani, Zaina |
| Author | Al-Kuwari, Einas |
| Author | Jeremijenko, Andrew |
| Author | Kaleeckal, Anvar Hassan |
| Author | Latif, Ali Nizar |
| Author | Shaik, Riyazuddin Mohammad |
| Author | Abdul-Rahim, Hanan F. |
| Author | Nasrallah, Gheyath K. |
| Author | Al-Kuwari, Mohamed Ghaith |
| Author | Al-Romaihi, Hamad Eid |
| Author | Butt, Adeel A. |
| Author | Al-Thani, Mohamed H. |
| Author | Al-Khal, Abdullatif |
| Author | Bertollini, Roberto |
| Author | Abu-Raddad, Laith J. |
| Available date | 2023-03-28T07:44:50Z |
| Publication Date | 2023-03-01 |
| Publication Name | The Lancet Infectious Diseases |
| Identifier | http://dx.doi.org/10.1016/S1473-3099(23)00005-1 |
| Citation | Chemaitelly H, Ayoub HH, Coyle P, Tang P, Yassine HM, Al Thani AA, Al-Khatib HA, Hasan MR, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Al-Romaihi HE, Butt AA, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ. BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents. Lancet Infect Dis. 2023 Mar;23(3):276-277. doi: 10.1016/S1473-3099(23)00005-1. |
| ISSN | 14733099 |
| Abstract | COVID-19 vaccine antigen dose might affect protection against SARS-CoV-2 infection,1, 2 but direct evidence to quantify this effect is absent. We conducted a matched, retrospective, cohort study using a regression discontinuity design3 to emulate a randomised controlled trial in Qatar between Feb 3, 2022, and Nov 8, 2022, to provide a head-to-head, controlled comparison of protection induced by two different antigen doses of the BNT162b2 (Pfizer–BioNTech) vaccine (appendix pp 4–10). The study compared incidence of infection with the omicron (B.1.1.529) variant in the national cohort of adolescents aged 12 years who received the two-dose 30 μg BNT162b2 primary series with that in the national cohort of adolescents aged 11 years who received the two-dose pediatric 10 μg BNT162b2 primary series. |
| Language | en |
| Publisher | Elsevier |
| Subject | COVID-19 SARS-CoV-2 omicron infection |
| Type | Other |
| Pagination | 276-277 |
| Issue Number | 3 |
| Volume Number | 23 |
| ESSN | 1474-4457 |
Check access options
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [700 items ]
-
Biomedical Sciences [687 items ]
-
Mathematics, Statistics & Physics [689 items ]
-
Public Health [397 items ]